Overview

RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

This will be an open-label, non-randomized, absorption, metabolism, and excretion study of Lurasidone administered in a suspension at 40 mg to 6 normal healthy male subjects in a postprandial state

Phase:

Phase 1

Details

Lead Sponsor:

Sunovion

Treatments:

Lurasidone Hydrochloride